The U.S. authorities, as part of the fight against coronavirus COVID-19, authorized the emergency use of a cocktail of antibodies from the pharmaceutical company Eli Lilly. This is stated on the website of the U.S. Food and Drug Administration (FDA).
The FDA has approved the use of bamlanivimab and etesivimab. Their co-injection is used to treat mild to moderate forms of COVID-19 in adults and children over 12 years of age with a bodyweight of at least 40 kilograms who have been identified with coronavirus tests, as well as in people at high risk of developing a severe form of the disease.
Last November, the U.S. allowed some coronavirus patients to be treated with a “cocktail” of REGN-COV2 antibodies from U.S. biotechnology company Regeneron Pharmaceuticals, which President Donald Trump took during his illness. However, patients who require oxygen therapy or hospitalization will not receive this “cocktail.